Stability indicating RP-HPLC method for the simultaneous estimation of Olaparib & Bevacizumab in pharmaceutical dosage forms

Q3 Pharmacology, Toxicology and Pharmaceutics

Research Journal of Pharmacy and Technology Pub Date : 2024-02-20 DOI:10.52711/0974-360x.2024.00141

Shanthi Priya DK, M. Mathrusri Annapurna

引用次数: 0

Abstract

Olaparib and Bevacizumab are anti-cancer agents. A new stability indicating RP-HPLC technique has been developed and validated for the simultaneous assay of Olaparib and Bevacizumab using Inertsil ODS column with UV detection at 258 nm within a run time of 6 minutes where Olaparib was eluted at 2.336 min and that of Bevacizumab at 4.873 min. Linearity was observed over the concentration range 37.50-225 µg/mL for Olaparib and 6.25-37.50 µg/mL for Bevacizumab respectively and the regression equations were found to be y=16815.19x+22410.75 and y=14512.58x+2387.04 for Olaparib and Bevacizumab respectively. The LOD was found to be 0.9 μg/ml and 0.1500 μg/mL whereas the LOQ was found to be 3.00 μg/mL and 0.5000 μg/mL for Olaparib and Bevacizumab respectively.

查看原文本刊更多论文

同时估算药物剂型中奥拉帕利和贝伐珠单抗含量的稳定性指示 RP-HPLC 方法

奥拉帕利（Olaparib）和贝伐珠单抗（Bevacizumab）是抗癌药物。使用 Inertsil ODS 色谱柱，在 258 纳米波长处进行紫外检测，在 6 分钟的运行时间内，奥拉帕利在 2.336 分钟洗脱，贝伐珠单抗在 4.873 分钟洗脱。奥拉帕利和贝伐珠单抗的线性范围分别为 37.50-225 µg/mL 和 6.25-37.50 µg/mL，回归方程分别为 y=16815.19x+22410.75 和 y=14512.58x+2387.04。发现奥拉帕利和贝伐珠单抗的最低检测限分别为 0.9 μg/ml 和 0.1500 μg/mL，而最低检测限分别为 3.00 μg/mL 和 0.5000 μg/mL。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Research Journal of Pharmacy and Technology Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal, devoted to pharmaceutical sciences. The aim of RJPT is to increase the impact of pharmaceutical research both in academia and industry, with strong emphasis on quality and originality. RJPT publishes Original Research Articles, Short Communications, Review Articles in all areas of pharmaceutical sciences from the discovery of a drug up to clinical evaluation. Topics covered are: Pharmaceutics and Pharmacokinetics; Pharmaceutical chemistry including medicinal and analytical chemistry; Pharmacognosy including herbal products standardization and Phytochemistry; Pharmacology: Allied sciences including drug regulatory affairs, Pharmaceutical Marketing, Pharmaceutical Microbiology, Pharmaceutical biochemistry, Pharmaceutical Education and Hospital Pharmacy.